To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Targeted Therapeutics Market size was valued at USD 75.25 Billion in 2024 and is poised to grow from USD 77.36 Billion in 2025 to USD 96.48 Billion by 2033, growing at a CAGR of 2.8% during the forecast period (2026–2033). 

    Global targeted therapeutics market is highly competitive with the presence of local as well as global companies. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of global targeted therapeutics market. 'Roche (Switzerland) ', 'Novartis (Switzerland) ', 'Pfizer (USA) ', 'Merck & Co. (USA) ', 'Bristol-Myers Squibb (USA) ', 'AstraZeneca (UK) ', 'Amgen (USA) ', 'GlaxoSmithKline (UK) ', 'Sanofi (France) ', 'Bayer (Germany) ', 'Eli Lilly and Company (USA) ', 'Johnson & Johnson (USA) ', 'AbbVie (USA) ', 'Takeda Pharmaceutical (Japan) ', 'Gilead Sciences (USA) ', 'Biogen (USA) ', 'Regeneron Pharmaceuticals (USA) ', 'Celgene (USA) (Acquired by Bristol-Myers Squibb) ', 'Incyte (USA) ', 'In January 2024, Remix Therapeutics started a strategic collaboration with Roche, which is pointed toward utilizing RNA modulation for novel drug discovery efforts.', 'In October 2023, Medilink Therapeutics uncovered a strategic collaboration and overall license agreement with BioNTech to advance the improvement of the cutting-edge enemy of cancer antibody drug forms.', 'In October 2023, Monte Rosa Therapeutics disclosed a strategic collaboration with Roche to discover novel molecular glue degraders targeting malignant growth and neurological diseases.'

    Increasing prevalence of cancer and disposable income of people

    Major players in the global therapeutics market are heavily involved in collaboration agreements and acquisitions as well as new product launches. These initiatives are expected to fuel the growth of the global therapeutics market. Some key competitors in the therapeutics market have adopted expansion strategies. For example, PubMed Inc. has launched its upgraded versions of complement-targeted therapies to cater to various destructive potentials for several diseases and pathological conditions, boosting the sales of complement-targeted therapies.

    On the basis of region, global targeted therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. North America dominated the global market. This is because the biologics industry in North America is expanding rapidly. The presence of various biotechnology companies in this sector has contributed significantly to the growth of the market. Also, increased investment, along with government support for the development and expansion of biopharmaceutical manufacturing facilities, is expected to boost the targeted therapeutics market in North America.

    Feedback From Our Clients

    Global Targeted Therapeutics Market

    Report ID: SQMIG35H2052

    $5,300
    BUY NOW